

Activity Outline
Topics in Public Health: Advancing maternal health: series on maternal morbidity, mortality and clinical research
September 16, 2022
Webinar

Activity Coordinators:

Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov), Jessica Voqui (jessica.voqui@fda.hhs.gov)

Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description

Advancing maternal health (presentation 1)

The purpose of the presentation is to highlight maternal health programs funded by HRSA's Maternal and Child Health Bureau. Programs covered will include the Alliance for Innovation on Maternal Health Innovation, the Maternal Health Learning & Innovation Center, the State Maternal Health Innovation Program, and the Women's Preventive Services Initiative. Participants will learn how they can engage with these activities to widen HRSA's footprint in responding to the maternal mortality and severe maternal morbidity crisis.

Advancing Clinical Research in Pregnant and Lactating People (presentation 2)

There were 3.6 million births in the United States in 2021. Pregnant and lactating people need treatments for medical conditions; however, there are gaps in available human data, which makes it difficult to inform the safe use of prescription drugs in pregnant and lactating people. This presentation will 1) provide an overview of FDA efforts to advance research in pregnant and lactating people, 2) discuss the types of studies that are enrolling pregnant and lactating people and 3) provide information for how healthcare providers can become involved in advancing research in pregnant and lactating people.

References

- Health Resources & Services Administration's Maternal & Child Health webpage. Available from: <https://mchb.hrsa.gov/programs-impact/focus-areas/maternal-health>
- Maternal Health Learning and Innovation Center: Maternal Resource Repository webpage. Available from: <https://maternalhealthlearning.org/resources/>
- Alliance for Innovation on Maternal Health webpage. Available from: <https://saferbirth.org/patient-safety-bundles/>
- Vital Statistics Rapid Release. Report No. 20. May 2022. <https://www.cdc.gov/nchs/data/vsrr/vsrr020.pdf>.
- Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. *BMJ Open* 2014;4:e004365.
- Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. *Am J Obstet Gynecol.* 2011;205(1):51.e1-8.

Series Objectives

- Increase awareness of current topics in public health
- Help improve patient/public health outcomes
- Help participants modify their practice within their job or deployments

Learning Objectives After completion of this activity, the participant will be able to:

- Summarize the current issues in maternal health. (presentation 1).
- Increase awareness of HRSA/MCHB's recent investments (presentation 1).
- Learn about innovative initiatives to improve maternal health (presentation 1).
- Discuss opportunities to collaborate to improve maternal health (presentation 1).
- Describe the data gaps that exist regarding the use of medications in pregnant and lactating people (presentation 2).
- Discuss FDA efforts to advance research in pregnant and lactating people (presentation 2).
- Describe types of studies that are currently enrolling pregnant and lactating people (presentation 2).
- Examine how healthcare providers can become involved and have an impact in advancing research in pregnant and lactating people (presentation 2).

Target Audience

This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, This activity is intended for physicians, pharmacists, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health..

Agenda

Lecture 1 September 16, 2022

TIME	TOPIC	SPEAKER
2:00 - 3:00 PM EDT	Advancing maternal health: series on maternal morbidity, mortality and clinical research	Miriam Dinatale, DO Kimberly Sherman, MPH, , MPP

Continuing Education Accreditation



In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-22-026-L04-P, and ACPE Universal Activity Number JA0002895-0000-22-026-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- Dinatale, Miriam, DO, Team Leader, Food and Drug Administration - nothing to disclose
- Sherman, Kimberly, MPH, , MPP, Chief, Maternal & Women's Health, HHS/HRSA - nothing to disclose

Planning Committee

- BIRCH-SMITH, POSTELLE, PharmD - nothing to disclose
- Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose
- Januszewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/ODLDC - nothing to disclose
- La, Thang, PharmD, MPH, Central Triage Unit Manager, FDA/CDER/OSE/RSS - nothing to disclose
- Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS - nothing to disclose
- McClain, Rena, PharmD, CMS - nothing to disclose
- Nabavian, Sadaf, Senior Regulatory Project Manager, FDA - nothing to disclose
- Radden, Erica - nothing to disclose

CE Consultation and Accreditation Team

- Catherine Harrison, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated. All relevant financial relationships have been mitigated.

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.